W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
A Phase II study of oxaliplatin in urothelial cancer.
Eric Winquist,Everett E. Vokes,Malcolm J. Moore,L. Philip Schumm,Kristin Hoving,Walter M. Stadler +5 more
TL;DR: In this article, a double-arm two-stage Phase II trial was conducted to assess the antitumor activity of oxaliplatin, a third generation platinum derivative with a 1,2-diaminocyclohexane (DACH) carrier ligand, in patients with metastatic transitional cell carcinoma of the bladder.
Journal ArticleDOI
857 randomized phase iii trial of sorafenib in advanced renal cell carcinoma (rcc): impact of crossover on survival
Timothy Eisen,Ronald M. Bukowski,Michael Staehler,Cezary Szczylik,Stéphane Oudard,Walter M. Stadler,Ronit Simantov,M. Shan,Bernard Escudier +8 more
TL;DR: The lower HR observed after censoring placebo patients crossed over to sorafenib suggests a continued beneficial effect of sorafinib, the first novel, oral approved treatment for advanced RCC in more than a decade.
Journal ArticleDOI
Study of cohort-specific consent and patient control in phase I cancer trials.
Christopher K. Daugherty,Mark J. Ratain,Hironobu Minami,Donald M. Banik,Nicholas J. Vogelzang,Walter M. Stadler,Mark Siegler +6 more
TL;DR: A clinical trial design that uses an interactive informed consent process in which patient-subjects can choose to become directly involved in decisions of dose escalation may reduce the magnitude of many of the commonly recognized ethical dilemmas associated with this form of clinical research.
Journal ArticleDOI
Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers
Daniel J. George,M.D. Michaelson,Jonathan E. Rosenberg,Ronald M. Bukowski,J. A. Sosman,Walter M. Stadler,Kim Margolin,Thomas E. Hutson,B. I. Rini +8 more
TL;DR: This study evaluated the safety and activity of sunitinib in mRCC patients previously treated with the VEGF-neutralizing antibody, bevacizumab, and levels of angiogenic biomarkers, including plasma VEGf and soluble VEGFR-3, were assessed for predictive significance with clinical response.
Journal Article
Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization.
Walter M. Stadler,Gary D. Steinberg,Ximing J. Yang,Fitsum Hagos,Craig Turner,Olufunmilayo I. Olopade +5 more
TL;DR: The proposition that chromosome 9 losses occur early in bladder oncogenesis and before p53 alterations or development of aneusomy is strengthened, as the observed homozygous deletions strengthen the hypotheses that CDKN2 and DBCCR1 are important tumor suppressor genes.